Drugs, prescribed drugs, purpose: violation of the synthesis of sex hormones, normalization of hormone levels.
Sustanon-250 dosage form is a solution for intramuscular injection: oily, yellow to almost colorless with a light yellow tint.
Testosterone replacement therapy in men with pathological conditions associated with primary and secondary hypogonadism, both congenital and acquired.
Testosterone is the major endogenous hormone necessary for the normal growth and development of male reproductive organs and male secondary sexual characteristics. Testosterone is important in all adult men for the function of the testicles and related structures, as well as for the maintenance of libido, well-being, erectile strength and for the function of the prostate and seminal vesicles. Treatment of hypogonadal men with Sustanon-250 results in a clinically significant increase in plasma concentrations of testosterone, dihydrotestosterone, estradiol and androstenedione, as well as a decrease in the level of SHBG (sex hormone binding globulin); Levels of luteinizing hormone (LT) and follicle-stimulating hormone (FSH) return to normal. Treatment with Sustanon-250 leads to a reduction in the symptoms of testosterone deficiency. Bone mineral density and muscle mass also increase, and body weight decreases in obese patients. During treatment, sexual functions will return to normal, including erectile function and libido. When using the drug, serum concentrations of HDL (high-density lipoproteins), LDL (low-density lipoproteins) and triglycerides decrease, hemoglobin and hematocrit concentrations increase, while there is no clinically significant change in liver enzymes and PSA (antigen-specific prostate). The drug can cause prostate enlargement, while functional changes are not observed. In men with hypogonadal diabetes, androgen use improves insulin sensitivity and / or decreases plasma glucose concentrations. In boys with stunted growth and puberty, the use of androgens accelerates growth and encourages the development of secondary sexual characteristics. Treating trans women with androgens such as Sustanon-250 promotes masculinization.
- in prepubertal boys to avoid premature epiphyseal closure and early puberty;
- chronic heart failure, renal and / or hepatic failure, to prevent the development of edema;
- diabetes mellitus;
- prostate hypertrophy with symptoms of urinary retention;
- sleep apnea and risk factors such as obesity and chronic lung disease;
- Known or suspected prostate cancer or breast cancer;
- Hypersensitivity to any component of the drug;
- Children under 3 years (due to the content of benzyl alcohol in the preparation).